Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.
Neutralization of human papillomavirus type 11 (HPV-11) has been demonstrated using serum and cervical secretions from primates vaccinated with virus-like particles (VLPs). Theoretically, neutralizing antibodies could protect women from HPV infection. The immunogenicity of a yeast-derived HPV-11 L1 VLP vaccine was tested in women. Serum specimens were evaluated for HPV-11 titer by competitive radioimmunoassay (cRIA) and for neutralization by use of the athymic mouse xenograft system. Analysis of serum from 104 subjects showed a dose response in HPV-11 cRIA titers and neutralization. Overall, 68 (82.9%) of 82 postimmunization serum specimens from VLP recipients were 100% neutralizing when used in the assay at a 1:50 dilution. Of 69 serum specimens, 63 (91.3%) with cRIA titers >200 milliMerck units per milliliter were neutralizing. Immunization with HPV VLPs elicits a vigorous serum immune response in a high percentage of women. The HPV-11 cRIA titer appears to be a surrogate marker for neutralization.
Brown
D R
DR
Indiana University School of Medicine and Roudebush Veterans Administration Hospital, 545 Barnhill Dr., Indianapolis, IN 46202, USA. darbrow@iupui.edu
Bryan
J T
JT
Schroeder
J M
JM
Robinson
T S
TS
Fife
K H
KH
Wheeler
C M
CM
Barr
E
E
Smith
P R
PR
Chiacchierini
L
L
DiCello
A
A
Jansen
K U
KU
D000293:Adolescent; D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D051379:Mice; D009500:Neutralization Tests; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000821:virology; D011863:Radioimmunoassay; D014412:Tumor Virus Infections / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014771:Virion / Q000276:immunology*; D015003:Yeasts / Q000235:genetics
D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014765:Viral Vaccines